Navigation Links
Biodesix Supports Unique Lung Cancer Research Initiative
Date:4/28/2011

BROOMFIELD, Colo., April 28, 2011 /PRNewswire/ -- Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as "Alchemy"). The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community medical centers in the United States. The study collects biospecimens and data from lung cancer patients in order to facilitate and accelerate the development and delivery of diagnostic tests and treatments tailored to the individual patient. As part of the study, Biodesix is performing VeriStrat® testing on eligible patients and serving as ALCMI's biorepository for all serum samples collected from CASTLE study subjects for future research. VeriStrat is a serum proteomic test for advanced non-small cell lung cancer patients that helps physicians determine if a patient should receive treatment with a drug called erlotinib.

Biodesix is committed to advancing the field of personalized medicine by developing unique and clinically useful diagnostic tests in oncology. This collaboration is the first of its kind in bringing together leading lung cancer scientists in the U.S. and Europe, patient advocates, and diagnostic laboratories to collect biospecimens with the intent of developing personalized therapies and tests that could improve patient outcomes. "We are pleased to offer the only serum-based testing for the CASTLE study and play an integral role in this collaboration" commented Paul Beresford, Biodesix' Vice President in charge of the company's laboratory operations. "We look forward to supporting our ALCMI colleagues in their efforts to accelerate translational medicine in lung cancer and continuing to shift the standard of care toward widespread use of molecular testing in clinical decision-making."

About NSCLC: As reported by the American Cancer Society, lung cancer is the leadi
'/>"/>

SOURCE Biodesix
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The SCOOTER Store Supports Fight Against Multiple Sclerosis
2. Alzheimers Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
3. Home Medical Equipment Group Supports Bipartisan Bill to Repeal the Controversial Medicare Competitive Bidding Program for Homecare
4. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
5. Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event
6. Leader Ventures Supports Innovative Drug Discovery Company Carmot
7. Red Cross Supports Pan American Health Organization with $1.5 Million in Medicine and Supplies for Cholera Response
8. Philips Announces Its Portfolio of Lifesaving Solutions Supports New American Heart Association 2010 CPR and ECC Guidelines
9. Netsmart Technologies Software Supports Shawnee Mental Health Center Integrated Mental Health and Primary Care Initiative
10. Alliance Seating & Mobility Supports Community Efforts to Help Paralyzed North Carolina Resident
11. New Mask Study Supports CDCs Updated Guidance for Seasonal Flu Prevention Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014  Hanger, Inc. (NYSE: HGR ... results of operations for the quarter ended September 30, ... closes.  A conference call to discuss these results is ... November 7, 2014. Those wishing to participate should call ... 14, 2014 by dialing 1-855-859-2056 and referencing Conference ID ...
(Date:10/17/2014)... October 17, 2014 ... has announced the addition of the  "China ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in China impacted ... in consumption concept, dietary habit, way of ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
... Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication ... June 9 A new analysis demonstrated that ... severely active rheumatoid arthritis (RA) who had prior ... received subcutaneous injections of SIMPONI(TM) (golimumab) once every ...
... in June Issue of Circulation , , SILVER ... Corporation (Nasdaq: UTHR ) and Eli Lilly ... the results of a pivotal 16-week study showing that ... improved exercise capacity and improved time to clinical worsening ...
Cached Medicine Technology:New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Based on a proprietary chromatid-specific ... assays capable of determining DNA sequence, location and ... three dimensions of high-resolution data, dGH assays are ... range of disease-causing genetic rearrangements, including chromosomal inversions ... tools, including today’s advanced sequencing technologies. , According ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
(Date:10/19/2014)... 20, 2014 Recently, BambooIndustry.com, one of ... its new range of bamboo deckings . Moreover, ... natural items; they are now available at deeply discounted ... it is hard to overstate the significance of online ... to online services. The company’s workers are striving to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many kinds ... designs of 2014 mother of the bride dresses ... offered with big discounts, up to 70% off. All ... enjoy this special offer. , Owing to the ... one of the leading brands in the global market. ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading provider ... its Board of Directors has approved the,repurchase of an ... Stock over,the next 12 months. The Company,s Board of ... review of the Company,s financial position and,investment alternatives. The ...
... Fla. -- With a four-year, $707,000 grant from the American ... the Florida State University College of Medicine, hopes to learn ... on the runaway cell division process that occurs in many ... an enzyme known as Cdc14 in deactivating the cell division ...
... Genomatix Software GmbH, a Systems Biology company focussed on ... has begun showcasing its abilities in the analysis of ... Allan P. Boyle et al published in the January ... and Characterization of Open Chromatin across the Genome where ...
... 32% to $14.2 Million ... Quarterly Record, MINNEAPOLIS, Feb. 25 ATS Medical, Inc.,(Nasdaq: ... and services, today reported financial results for the,fourth quarter and ... $14.2 million, up 32.4% from $10.7 million reported in the,fourth ...
... never filled after hospital discharge, study found , , MONDAY, Feb. ... survive heart attacks don,t take the drugs prescribed for them ... That failure to adhere to medication increases the patient,s risk ... "About one in five of all prescriptions weren,t filled after ...
... Corp. and Capital Growth Planning Inc., form "MaxLife-CGP",Partners LLC., a ... approximately $25M to $100M dollars in face value, ... 1 ... throughout 2008., CALIFORNIA, Feb. 25 /PRNewswire-FirstCall/ - MaxLife Fund ...
Cached Medicine News:Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 2Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 3Health News:FSU College of Medicine researcher seeks to uncover new cancer therapies 2Health News:Genomatix integrates genome-wide open chromatin from next generation sequencing 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 3Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 4Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 5Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 6Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 7Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 8Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 9Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 10Health News:Many Patients Fail to Take Drugs After Heart Attack 2Health News:Many Patients Fail to Take Drugs After Heart Attack 3Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 2Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 3
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Antigenic Total Protein S, ELISA Method...
Medicine Products: